Imaging Technologies and Transdermal Delivery in Skin Disorders 2019
DOI: 10.1002/9783527814633.ch8
|View full text |Cite
|
Sign up to set email alerts
|

Topical and Transdermal Delivery with Chemical Enhancers and Nanoparticles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 127 publications
0
2
0
Order By: Relevance
“…23,24 However, their use is restricted due to local intolerance and difficulties in therapeutic feasibility. 25 In our previous studies, we developed skin-permeating liposomes that could deliver macromolecules such as peptides and nucleic acids across deeper dermal layers. 26,27 Taking cues from previous findings, in the present study, we designed and developed novel twin-chain conjugated lithocholic analogues LC6, LC8, LC10, and LC12 (Figure 1A) to reduce keratinocyte hyperproliferation and hyperimmune responses together by modulating EphA2 levels and activate the VDR to combat (Figure 1B).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…23,24 However, their use is restricted due to local intolerance and difficulties in therapeutic feasibility. 25 In our previous studies, we developed skin-permeating liposomes that could deliver macromolecules such as peptides and nucleic acids across deeper dermal layers. 26,27 Taking cues from previous findings, in the present study, we designed and developed novel twin-chain conjugated lithocholic analogues LC6, LC8, LC10, and LC12 (Figure 1A) to reduce keratinocyte hyperproliferation and hyperimmune responses together by modulating EphA2 levels and activate the VDR to combat (Figure 1B).…”
Section: Introductionmentioning
confidence: 99%
“…Delivery of therapeutic molecules into deeper layers of the skin is the primary technical challenge due to lipophilic nature of the stratum corneum (SC) that limits the transport of therapeutic payloads into the deeper layers. , To overcome the limitation, skin permeation enhancers such as N-methyl-2-pyrrolidone (NMP) and azones were developed. , However, their use is restricted due to local intolerance and difficulties in therapeutic feasibility . In our previous studies, we developed skin-permeating liposomes that could deliver macromolecules such as peptides and nucleic acids across deeper dermal layers. , …”
Section: Introductionmentioning
confidence: 99%